PTC Therapeutics, Inc. PTCT

Health CarePharmaceuticalsUnited States of America

Last close 60.88 USD on Nov 2, 2026, −19.9% year to date

Quant rating

Quant rating B Rank 206 of 565 in Health Care

Growth A 15 of 565
Valuation B 202 of 565
Quality B 216 of 565
Revisions C 291 of 565
Momentum C 347 of 565

Wall Street consensus Buy (1.80)Average target 100.47 USD +65.0%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 5.1B
Enterprise value: 5.8B
52-week range: 58.80 – 90.86
3-year range: 18.07 – 90.86
Dividend yield: –
Beta (5 years): 0.51
Shares outstanding: 83.5M
Next earnings: Feb 17, 2027

About the company

PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.

Growth and profitability fiscal year ends December 31

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	1,731	807	938	699	539	–
Revenue growth	114.5%	−14.0%	34.2%	29.7%	41.4%	35.4%
EPS (basic, normalized)	7.78	−6.03	−6.53	−7.33	−7.43	–
EPS growth	–	–	–	–	–	–
Gross margin	97.3%	92.9%	93.0%	93.6%	94.0%	94.2%
Net margin	39.4%	−45.0%	−66.8%	−80.0%	−97.3%	−49.9%
ROE	–	–	–	–	−216.7%	−216.7%

Balance sheet, last quarter
Cash & short-term investments (mil)	2,128
Current ratio	3.27x
Long-term debt (mil)	2,523
Net debt (mil)	717
Total equity (mil)	−191
Net debt / equity	−3.75x
Net debt / EBITDA	0.79x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	1,731	+114.5%	3.4x	906	+2,254.8%	6.4x	7.78	+229.0%	7.8x
2026	1,323	−23.5%	4.4x	338	−62.7%	17.2x	0.82	−89.5%	74.2x
2027	1,461	+10.5%	4.0x	503	+48.7%	11.5x	2.41	+194.0%	25.2x
2028	1,631	+11.6%	3.6x	702	+39.8%	8.3x	3.89	+61.1%	15.7x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	1,323	+4.6%	+4.2%	+30.5%	0.82	−53.6%	−52.1%	+250.7%
2027	1,461	+3.3%	+4.3%	+20.1%	2.41	+4.7%	+5.7%	+83.9%
2028	1,631	−1.9%	−0.5%	+11.0%	3.89	+2.6%	+10.9%	+26.9%

Earnings surprises EPS beat in 2 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	210	187	197	213	1,176	179	211	213	273	361
Sales mean (mil)	170	185	173	232	168	171	185	277	219	299
Surprise	+23.8%	+0.7%	+14.0%	−8.3%	+599.0%	+4.6%	+13.9%	−22.9%	+24.6%	+20.6%
EPS reported	−1.20	−1.27	−1.39	−2.15	10.04	−0.83	0.20	−1.67	−0.03	0.92
EPS mean	−1.24	−1.05	−1.44	−0.66	−0.21	−1.06	−1.37	0.04	−0.47	0.42
Surprise	+3.3%	−21.1%	+3.6%	−227.7%	−4,835.8%	+21.8%	−114.6%	−4,553.3%	+93.6%	+120.7%

Peer comparison Pharmaceuticals

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
PTCT PTC Therapeutics, Inc.	5.1B	0.79x	39.4%	−26.60x	74.2x	25.2x	17.2x	11.5x
ROPC Roche Holding AG	391.3B	–	20.9%	9.68x	19.6x	18.1x	13.7x	12.8x
NOVN Novartis AG	324.4B	1.71x	24.8%	8.09x	18.2x	16.4x	15.5x	14.1x
PFE Pfizer Inc.	174.8B	2.19x	12.4%	2.05x	10.4x	10.6x	9.4x	9.4x
VRTX Vertex Pharmaceuticals Incorporated	140.2B	−1.44x	32.9%	6.92x	29.5x	26.4x	23.3x	20.6x
REGN Regeneron Pharmaceuticals, Inc.	99.4B	−1.26x	31.7%	3.06x	14.5x	13.7x	12.2x	11.1x
Mean		0.40x	27.0%	0.53x	27.7x	18.4x	15.2x	13.2x
Median		0.79x	28.3%	4.99x	18.9x	17.2x	14.6x	12.1x

Technical analysis

1M−4.1%
3M−10.5%
1Y−10.9%
3Y+236.9%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, PTC Therapeutics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	1,731	807	938	699	539	381
Cost of revenue	47.0	57.4	65.5	44.7	32.3	18.9
Gross profit	1,684	749	872	654	506	362
Selling, general & administrative expenses	347	301	333	326	286	245
Research & development	455	534	667	651	541	478
Depreciation/amortization	24.7	60.7	223	117	54.8	36.9
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	−9.6	60.4	355	33.4	0	10.6
Other operating expenses	−0.8	−4.5	−128	−25.9	−0.5	23.3
Operating income	867	−203	−577	−447	−374	−432
Net interest income (expense)	−164	−169	−125	−110	−100	−56.4
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	−6.8	8.1	6.1	−30.5	−43.5	85.2
Net income before taxes	697	−363	−696	−587	−518	−403
Provision for taxes	14.0	0.2	−69.5	−28.5	5.6	35.2
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	683	−363	−627	−559	−524	−438
Extraordinary items	–	–	–	–	–	–
Net income	683	−363	−627	−559	−524	−438
EBIT, normalized	857	−142	−189	−414	−374	−421
EBITDA, normalized	896	−66.6	47.7	−285	−310	−378
Basic EPS, normalized	7.78	−6.03	−6.53	−7.33	−7.43	–

Balance sheet in millions of USD, fiscal years

Balance sheet, PTC Therapeutics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	1,945	1,140	877	411	773	1,104
Receivables	182	159	161	156	110	69.9
Total inventory	79.6	23.2	30.6	21.8	15.9	18.7
Prepaid expenses	67.3	44.1	150	106	54.7	39.5
Other current assets	0	0	0	0	0	0
Total current assets	2,274	1,366	1,219	694	954	1,232
Property, plant & equipment	135	118	179	175	130	118
Goodwill	82.3	82.3	82.3	82.3	82.3	82.3
Intangibles	389	119	379	706	725	715
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	18.3	20.7	36.2	48.6	46.5	60.6
Total assets	2,899	1,705	1,896	1,706	1,938	2,208
Liabilities
Accounts payable	45.5	17.3	6.0	27.3	23.0	18.7
Payable/accrued	129	58.6	77.2	63.8	61.7	54.3
Accrued expenses	128	112	116	126	106	92.0
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	573	261	197	75.1	212	22.3
Other current liabilities	93.4	132	206	114	107	90.1
Total current liabilities	968	581	603	406	509	277
Long-term debt	2,028	2,125	1,921	1,276	977	991
Minority interest	–	–	–	–	–	–
Other liabilities	107	97.2	190	370	451	458
Total liabilities	3,104	2,803	2,714	2,053	1,937	1,726
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0.1	0.1	0.1	0.1	0.1	0.1
Additional paid-in capital	2,748	2,575	2,466	2,305	2,124	2,172
Retained earnings (accumulated deficit)	−2,964	−3,647	−3,284	−2,657	−2,098	−1,629
Treasury stock	–	–	–	–	–	–
Other equity	10.5	−25.9	−1.3	4.8	−24.3	−61.0
Total equity	−205	−1,098	−819	−347	1.4	482
Total liabilities & shareholders' equity	2,899	1,705	1,896	1,706	1,938	2,208

Cash flow statement in millions of USD, fiscal years

Cash flow statement, PTC Therapeutics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	683	−363	−627	−559	−524	−438
Depreciation, depletion & amortization	38.8	75.7	237	129	64.1	43.5
Deferred taxes	0	−55.9	−46.9	−34.3	0.4	5.9
Non-cash items	42.3	135	252	203	232	158
Changes in working capital	−52.6	101	26.3	−94.9	−23.8	36.9
Cash from operations	711	−108	−158	−357	−251	−194
Investing activities
Capital expenditures	−8.9	−6.5	−28.4	−32.0	−28.2	−17.8
Other investing cash flows	−853	50.7	−148	322	247	−544
Cash from investing	−862	44.2	−177	290	219	−562
Financing activities
Financing cash flow items	234	224	918	−51.9	0	611
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	97.4	32.3	−271	220	20.9	57.4
Cash from financing	331	256	646	168	20.9	669
Foreign exchange effects	22.7	−7.3	3.1	−2.8	−7.8	7.7
Net change in cash	203	185	314	98.7	−19.1	−79.2
Free cash flow	702	−114	−187	−389	−280	−212

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.